ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Anticoagulation for non-valvular atrial fibrillation: new anticoagulant agents [Anatol J Cardiol]
Anatol J Cardiol. 2013; 13(4): 379-384 | DOI: 10.5152/akd.2013.109

Anticoagulation for non-valvular atrial fibrillation: new anticoagulant agents

Alper Kepez1, Okan Erdoğan2
1Department of Cardiology, Faculty of Medicine, Marmara University İstanbul-Turkey
2Department of Cardiology, Faculty of Medicine, University of Marmara, İstanbul

Atrial fibrillation (AF) is a common cardiac arrhythmia and it is associated with systemic thromboembolism. Until recently, vitamin K antagonists (VKA) such as warfarin were the only available oral anticoagulant therapy for prevention of stroke and systemic embolism in AF. Limitations of VKA therapy have prompted researchers to search for novel anticoagulant drugs, which do not necessitate coagulation monitoring due to their more predictable pharmacokinetic profile. Large-scale phase III trials have been completed for some of these drugs and ‘U.S. Food and Drug Administration (FDA)’ approved dabigatran and rivaroxaban for prevention of systemic embolism in non-valvular AF patients. In this review, we will first focus on pharmacodynamic and pharmacokinetic profiles of these medications and then try to overview clinical trial results. We will also try to mention the current controversies regarding the clinical application of these drugs.

Keywords: Atrial fibrillation, stroke, systemic embolism, anticoagulation, vitamin K antagonists, novel anticoagulant drugs

Alper Kepez, Okan Erdoğan. Anticoagulation for non-valvular atrial fibrillation: new anticoagulant agents. Anatol J Cardiol. 2013; 13(4): 379-384
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 The Anatolian Journal of Cardiology



Kare Publishing is a subsidiary of Kare Media.